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                Introduction 
Metabolic syndrome (MetS) represents a constellation of 
abnormalities, including abdominal obesity, impaired glucose metabolism, 
dyslipidemia (hypertriglyceridemia, low HDL cholesterol) and 
hypertension, which identifies subjects at high risk for diabetes and 
cardiovascular diseases (Kasturi et al., 2008; Cornier et al., 2008; Eckel et 
al., 2010; Corona et al., 2011a).  
Different diagnostic criteria for MetS have been proposed over the 
years (see Appendix 1). In fact, the definition of parameters to be used for 
the diagnosis of MetS, as well as their thresholds, is under constant debate 
(Corona et al., 2009a, 2011a). Nonetheless, insulin resistance and increased 
adiposity have been universally recognized as the main features underlying 
MetS  (Cornier et al., 2008; Corona et al., 2009a, 2011a), although there is 
increasing evidence for other key components of the syndrome, such as 
oxidative stress, proinflammatory state or exaggerated sympathetic nervous 
system activation (Cornier et al., 2008). 
Several pathologic conditions other than diabetes and cardiovascular 
diseases are associated with MetS, including non-alcoholic fatty liver 
disease, polycystic ovarian syndrome, obstructive sleep apnea, 
lipodystrophy, and microvascular disease (Cornier et al., 2008). In addition, 
in the male, hypogonadism, erectile dysfunction and psychological 
disturbances are also often comorbid with MetS (Corona et al., 2006; 
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2011a, 2011b). Although a possible association between MetS and male 
infertility has also been hypothesized (Kasturi et al., 2008), it has never 
been demonstrated. Available animal models of MetS, both genetically- 
(Vartanian et al., 2006) and high fat diet- (Mallidis et al., 2011) induced, 
suggest that MetS is associated with deranged spermatogenesis and poor 
sperm quality . Several studies report a negative effect of the individual 
components of MetS also in the human male, however, the association 
between each MetS component, but not of MetS as a “category”, has been 
reported (see Kasturi et al., 2008).  
Among the components of MetS, overweight/obesity represent the 
more studied. However, the impact of overweight or obesity on the 
reproductive health of males has been only partially elucidated. In fact, 
although scientific interest in this issue has grown in the last years (see for 
review Hammoud et al., 2008; MacDonald et al., 2010; Sermondade et al., 
2012), available clinical studies investigating the relationship between 
obesity and male infertility are relatively poor compared to the extensive 
body of research investigating its association with  female infertility 
(Pasquali et al., 2007; Zain & Norman, 2008; Loret de Mola, 2009; Wilkes 
& Murdoch, 2009; Brewer & Balen, 2010; Rittenberg et al., 2011). Hence, 
while the relationship between obesity and female infertility is more than 
clear, the association with male infertility is still up for discussion 
(Hammoud et al., 2008; MacDonald et al., 2010). In addition, a recent 
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meta-analysis revealed little evidence for a relationship between obesity 
and poor semen parameters, despite a clear association with  hypogonadism 
(MacDonald et al., 2010). However, a more recent meta-analysis reported 
that overweight and obesity are both associated with an increased risk of 
azoospermia or oligozoospermia (Sermondade et al., 2012).  
In addition, in this last decade, a growing body of evidence has also 
documented an independent association between benign prostatic 
hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and obesity/MetS 
(Mongiu and McVary, 2008;  Moul and McVary, 2010; Gorbachinsky et 
al., 2010; Parsons, 2011; De Nunzio et al., 2012). In particular, we 
previously reported a positive correlation between MetS and BPH-related 
chronic inflammation in patients undergoing surgery for BPH (Vignozzi et 
al., 2013; Gacci et al., 2013). A recently published epidemiological survey 
of the Boston area (BACH) confirmed an association between MetS and 
LUTS; however, when subjects were stratified by age, the association was 
confirmed only in the youngest individuals (Kupelian et al., 2013). 
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                AIM OF THE THESIS 
Since MetS is essentially based on increased adiposity and it is 
associated with male hypogonadism (Corona et al., 2011a), erectile 
dysfunction, psychological disturbances (Corona et al., 2006), and 
BPH/LUTS (Mongiu and McVary, 2008;  Moul and McVary, 2010; 
Gorbachinsky et al., 2010; Parsons, 2011; De Nunzio et al., 2012), and all 
these factors might, in different ways, affect reproductive capacity 
(Hammerli et al., 2009), we investigated their possible correlations with 
MetS. Hence, we performed two studies.  
In the first study (study 1) we evaluated possible associations between 
MetS, semen and hormonal parameters, as well as clinical characteristics, 
including sexual, ultrasound and psychological characteristics, in a cohort 
of men with couple infertility.  
In the second study (study 2), we systematically investigated the 
possible associations between MetS and prostate-related symptoms and 
signs in a cohort of young men in infertile unions and tried to establish 
whether these associations correlate with fertility. 
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STUDY 1 
 
METABOLIC SYNDROME AND SEMINAL, SCROTAL 
ULTRASOUND AND PSYCHOBIOLOGICAL PARAMETERS IN 
MALES OF INFERTILE COUPLES 
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                       Materials and Methods 
Patients 
We studied a consecutive series of 376 male patients (mean age 
36.0±7.5 years) attending our Outpatient Clinic for the first time from 
January 2008 to December 2011, seeking medical care for couple 
infertility. Couple infertility was defined as the inability of a sexually 
active couple to achieve pregnancy despite unprotected intercourse for a 
period greater than 12 months, according to the World Health Organization 
(WHO, 2000). Subjects with karyotype abnormalities (n = 3), chromosome 
Y micro- deletions (n = 3)  and uni- or bilateral (n = 4 and n = 15, 
respectively) absence of vas deferens were excluded from the analysis. The 
socio-demographic and clinical characteristics of the sample are 
summarized in Table 1.  
All patients were evaluated before beginning any treatment. All 
patients enrolled underwent the usual diagnostic protocol applied to newly 
referred subjects at the Andrology Outpatient Clinic for infertility. All 
patients underwent a complete andrological and physical examination, with 
measurement of blood pressure (mean of three measurements 5 minutes 
apart, in sitting position, with a standard sphygmomanometer), height, 
weight and waist. In addition, scrotal ultrasound was routinely performed. 
All the data provided were collected as part of a routine clinical procedure 
and therefore, according to Italian law, approval from the local Ethical 
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Committee was not required. In addition, at the time of the first visit, all 
patients gave their written informed consent to have their clinical records 
included in a dedicated database and they were aware that their data, after 
having been made anonymous, would be used for clinical research 
purposes.   
 
Metabolic Syndrome (MetS) assessment 
MetS has been defined according to the International Diabetes 
Federation and the American Heart Association/National Heart, Lung, and 
Blood Institute (IDF&AHA/NHLBI, see Appendix 1) (Alberti et al., 2009) 
as the presence of three or more of the following five factors: central 
obesity (waist circumference > 102 cm), elevated triglycerides (≥ 1.7 
mmol/L or on drug treatment for elevated triglycerides), elevated blood 
pressure (BP ≥ 130 mm Hg systolic blood pressure or 85 mm Hg diastolic 
blood pressure or on antihypertensive drug treatment in a patient with a 
history of hypertension), elevated fasting glucose (≥ 5.6 mmol/L or on drug 
treatment for elevated glucose) and reduced high density lipoprotein (HDL) 
cholesterol (< 1.03 mmol/L or on drug treatment for reduced HDL 
cholesterol).  
 
Evaluation of erectile function 
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Patients were asked to complete the erectile function domain (EFD) 
(Cappelleri et al., 1999)of the International Index of Sexual Function-15 
(IIEF-15) (Rosen et al., 1997) (Appendix 2), in its Italian translation. An 
IIEF-15-EFD score of < 26 indicates erectile dysfunction (ED) (Cappelleri 
et al., 1999).  
 
Evaluation of premature ejaculation (PE) status 
Patients were asked to complete the Premature Ejaculation Diagnostic 
Tool (PEDT) (Symonds et al., 2007) (Appendix 3), in its Italian translation. 
PEDT is a brief, multidimensional, psychometrically validated, 5-item, 
self-reported questionnaire for diagnosing ejaculatory status, which 
provides scores for five subdomains, #1 control, #2 frequency, #3 minimal 
stimulation, #4 distress and #5 interpersonal difficulty. PEDT score was 
calculated as the sum of the scores of these domains. A PEDT score of ≤ 8 
indicates no-PE (Symonds et al., 2007).  
 
Screening of psychological traits 
Patients were asked to complete the Middlesex Hospital 
Questionnaire, modified (MHQ) (Crown & Crisp, 1966) (Appendix 4), a 
brief self-reported questionnaire for the screening of mental disorders, 
which provides scores for free-floating anxiety (MHQ-A), phobic anxiety 
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(MHQ-P), somatization (MHQ-S), obsessive-compulsive (MHQ-O), 
depressive (MHQ-D) and hysterical (MHQ-H) traits and symptoms.  
 
Colour-Doppler ultrasonography (CDU) 
All patients underwent scrotal CDU, using the ultrasonographic 
console Hitachi H21 (Hitachi Medical System, Tokyo, Japan). In order to 
prevent bias on the part of the examiner, scrotal CDU was performed 
intermittently by 2 experienced physicians (F.L. and G.C.), unaware of the 
clinical data. The CDU characteristics of the sample are summarized in 
Table 1.  
Scrotal CDU was performed in various longitudinal, transverse and 
oblique scans (Behre et al., 1995; Vicari, 1999, Lotti et al., 2011, 2012) 
using a 7.5 MHz high-frequency linear probe (L54M 6-13 MHz). 
Testicular and epididymal CDU features were examined according to 
previous studies (Behre et al., 1995; Vicari, 1999, Lotti et al., 2011, 2012; 
Isidori & Lenzi, 2008; Migaleddu et al., 2012). In particular, testis 
inhomogeneity (striated pattern) was defined as previously reported (Cohn 
et al., 1996; Loberant et al., 2010; Isidori & Lenzi, 2008; Migaleddu et al., 
2012) (see Fig. 1, panel A, inset). 
All patients underwent colour-Doppler assessment of penile arteries in 
the flaccid state with a 7.5-MHz high-frequency linear probe (L54M 6-13 
MHz), a pulsed Doppler investigation frequency of 5 MHz and a colour 
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flow mapping capability, according to previous studies (Mancini et al., 
2000; Corona et al., 2008a). The transducer was placed longitudinally on 
the ventral surface at the base of the penis. Colour flow mapping was 
helpful in obtaining an accurate angle corrected velocity with angle of 
insonation always < 45°, as previously reported (Mancini et al., 2000). 
 
Semen analysis, urine and seminal cultures and hormone evaluation 
All patients underwent, after the ultrasound session, semen analysis, 
performed according to the WHO criteria. Leukocytospermia was defined 
as leukocytes in seminal plasma ≥ 1 * 106/ml (WHO, 2010). In addition, 
urine and seminal cultures were routinely assessed in all men. 
Blood samples were drawn in the morning, after an overnight fast, for 
determination of blood glucose (by glucose oxidase method, Aeroset 
Abbott, Rome, Italy), HDL cholesterol and triglycerides (by automated 
enzymatic colorimetric method; Aeroset Abbott, Rome, Italy), LH, FSH, 
PRL,TSH, total testosterone (TT) by electrochemiluminescent method 
(Modular Roche, Milan, Italy) and sex hormone binding globulin (SHBG) 
by modular E170 platform electrochemiluminescence immunoassay 
(Roche Diagnostics, Mannheim, Germany). Calculated free testosterone 
was derived according to Vermeulen’s formula (available at http: 
//www.issam.ch/freetesto.htm) (Vermeulen et al., 1999). Biochemical 
hypogonadism has been defined for testosterone levels < 12 nmol/L (Wang 
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et al., 2009). Secondary or primary hypogonadism has been defined for  LH 
≤ 9.4 or > 9.4 U/L, respectively, according to Tajar et al. (2010). 
 
Identification of case patients and controls 
MetS was defined as described above. Subjects with 3 or ≥ 4 MetS 
components (n=15 and n= 12, respectively) were compared with controls 
selected from the same cohort with a 1:3 ratio (n=45 and n=36, 
respectively). For each case, the first three following patients within the 
same series with the same age (±4 years), body mass index (±2 kg/m
2
), TT 
levels (±4 nmol/L), smoking status (current/non-smoker), alcohol 
consumption (current/no consumption), past or present cryptorchidism 
(presence/absence), leukocytospermia (presence/absence), current positive 
urine and/or semen cultures (presence/absence)  were taken as a control. 
Associations with a p value < 0.05 were considered as significant. 
 
Data analysis 
Data were expressed as mean ± standard deviation (SD) when 
normally distributed,  as median (quartiles) for parameters with non-normal 
distribution, and as percentages when categorical. Correlations were 
assessed using Spearman’s or Pearson’s method whenever appropriate. 
Differences between more than two groups were assessed with one-way 
ANOVA or Kruskal-Wallis test, whenever appropriate. Unpaired two-sided 
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Student’s t tests were used for comparisons of means of normally 
distributed parameters. In all other cases, Mann–Whitney U-test was used 
for comparisons between groups. Relative risk and 95% confidence interval 
were calculated for association of categorical parameters, and chi-squared 
test was used for comparisons. Stepwise multiple linear or logistic 
regressions were applied for multivariate analysis, whenever appropriate. 
All statistical analysis was performed on SPSS (Statistical Package for the 
Social Sciences, Chicago, USA) for Windows 17.0. 
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                        Results 
Among the patients selected (mean age 36.0±8.0), 178 (50.7%) had no 
MetS components, 99 (28.2%) one, 47 (13.4%) two, 15 (4.3%) three, 8 
(2.3%) four and 4 (1.1%) five components. Overall, 27 (7.7%), satisfied 
MetS criteria, according to the IDF&AHA/NHLBI criteria. Subjects with 
MetS were older (43.7±10.4 vs 35.5±7.4; p<0.0001) and had significantly 
lower levels of  TT (13.8±6.5 vs 16.7±6.2; p<0.05) compared to the rest of 
the sample. No difference in the percentage of subjects with current 
smoking was found comparing MetS and no-MetS subjects (18.5 vs 28.5%, 
p=0.178). In addition, no difference in the frequency of those consuming 
alcohol was observed between the two groups (22.2 vs 25.6%, for MetS 
and no-MetS subjects, respectively; p=0.671). Subjects with diabetes 
mellitus were 3 (1.1%), representing 11.1% of the MetS group. The 
percentage of subjects under specific medications for MetS components 
(hypoglycaemic, n=3; lower-lipid, n=6; antihypertensive, n=14) in the 
whole sample and in the MetS group is reported in Table 1. 
Erectile dysfunction (ED), assessed by the IIEF-15-EFD score, was 
complained of by 69 (19.9%) patients, in particular by 46.2% and 16.7% of 
the MetS and no-MetS subjects, respectively. Premature ejaculation (PE), 
assessed by the PEDT score, was observed in 53 (15%) patients, 
particularly in 22.2% and 14.4% of the MetS and no-MetS subjects, 
respectively.     
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Etiological factors involved in male infertility: classification, 
prevalence and associations with MetS.  
Table 2 shows a patient stratification according to etiological factors 
involved in male infertility (as in Krausz, 2011), and the prevalence of 
MetS for each infertility factor. Possible associations between MetS and 
different causes of infertility have been investigated. A higher prevalence 
of secondary hypogonadism was found in subjects with MetS compared to 
the rest of the sample  (51.9 vs 17.6%, respectively; p< 0.0001). In contrast, 
a lower frequency of varicocele was observed in MetS subjects, according 
to both clinical and CDU criteria (Table 2). In particular, the presence of 
severe CDU varicocele was negatively associated with MetS (RR=0.28 
[0.08-0.97], p<0.05). No further association with other clinical 
abnormalities was observed (Table 2). In particular, no statistically 
significant difference in the prevalence of past or present cryptorchidism, 
leukocytospermia or current positive urine and/or semen cultures was 
observed comparing subjects with and without MetS (Table 2).  
In the same Table it is also reported the prevalence of MetS subjects 
under each clinical condition involved in male infertility. It is evident that 
secondary hypogonadism is the most common MetS-associated condition.  
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Ultrasonography testis parameters 
At univariate analysis, both testis and epididymal inhomogeneity were 
associated with MetS components (RR= 1.43 [1.16-1.76], p=0.001  and 
1.27 [1.03-1.57], p<0.05, respectively for each increment in the number of 
MetS components). In an age-adjusted logistic modelling, only testis 
inhomogeneity retained a significant association, and the HR for testis 
inhomogeneity as a function of MetS components was 1.36 [1.09-1.70], 
p<0.01 (for each increment in the number of MetS components, see Figure 
1A and 2A). These results were confirmed even after exclusion of subjects 
with diabetes mellitus (n=3) from the analysis (data not shown). Figure 2A 
shows associations between individual MetS components and testis 
inhomogeneity. After adjusting for age, the only factor significantly 
associated with testis inhomogeneity was increased waist (HR=2.25 [1.23-
4.09], p<0.01). 
No further association between MetS and other testicular ultrasound 
parameters, including volume, was observed (not shown).  
 
Hormonal and  seminal parameters 
Figure 1, panel B, shows that TT declines as a function of MetS 
components (p for trend at ANOVA <0.0001). This result was confirmed 
even after exclusion of subjects with diabetes mellitus (n=3) from the 
analysis (data not shown). Differences in TT levels between those having 2 
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or 3 MetS components were not statistically significant (p=0.263; Figure 1, 
panel B).  
Table 3 reports associations between MetS and hormonal parameters 
before and after adjusting for age. In an age-adjusted model, both TT and 
also calculated free T were negatively associated with MetS components, 
whereas gonadotropins, TSH and PRL were not (Table 3). These results 
were confirmed even after exclusion of subjects with diabetes mellitus 
(n=3) from the statistical analysis (data not shown). By using an age-
adjusted, iterative logistic modelling, we calculated the HR for 
hypogonadism (TT < 12 nmol/L) as a function of MetS components, taken 
together or individually (Figure 2B). Factors significantly associated with 
hypogonadism were increased waist (HR=3.1 [1.6-5.9], p=0.001), low 
HDL cholesterol (HR=2.4 [1.16-4.96], p<0.02), and high triglycerides 
(HR=2.4 [1.12-5.1], p<0.05). We also found that testis inhomogeneity was 
a risk factor  for hypogonadism, even after adjusting for age (HR=2.99 
[1.71-5.24], p<0.0001). We therefore introduced TT levels in the logistic 
model describing the association between MetS factors and testis 
inhomogeneity, as previously described (see before). Adding TT as a 
further covariate, besides age, significantly attenuated the relationship 
between number of MetS components and testis inhomogeneity (HR=1.24 
[0.98-1.56], p=0.07).  
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Table 1 shows semen parameters of the whole sample and of subjects 
with or without MetS. Since sexual abstinence had a wide variation in our 
population, eventually affecting semen parameters, the possible association 
between sexual abstinence and semen parameters has been investigated by 
univariate analysis, finding no correlation either in the whole sample or in 
MetS-stratified groups (data not shown). At univariate analysis, progressive 
motility and normal morphology were negatively related to number of 
MetS components (both p<0.0001 at ANOVA and Kruskal-Wallis, 
respectively). Since diabetes mellitus or current male genital infections 
may affect semen parameters, statistical analyses have been performed 
excluding iteratively subjects with diabetes mellitus (n=3), 
leukocytospermia (n=29) or current positive urine and/or semen cultures 
(n=25). After the exclusion of these subjects, previous associations were 
confirmed  at ANOVA for progressive motility and Kruskal-Wallis for 
normal morphology (data not shown). When age and TT were introduced 
as covariates in a multivariate model describing the relationships between 
MetS components and sperm parameters, only sperm morphology retained 
a significant association (B=-1.418±0.42; p=0.001) (see Figure 1, panel C). 
In addition, as smoking habit/alcohol consumption and use of medications 
might negatively affect sperm parameters, these confounders were 
iteratively introduced as further covariates in the aforementioned  
multivariate model.  Neither smoking/drinking habit nor use of medications 
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were associated with abnormal  sperm morphology   while MetS still 
resulted a statistically significant determinant in both models (B=-
1.318±0.45; p=0.003 and B=-1.333±0.24; p<0.005, respectively).  
Figure 2, panel C, reports, as a Forest Plot the HR for abnormal 
morphology (< 4%, WHO 2010) as a function of individual MetS 
components and MetS overall. In an age- and testosterone-adjusted logistic 
model, only hypertension was associated with abnormal morphology 
(HR=1.99 [1.11-3.54], p=0.02). The percentage of normal sperm 
morphology (≥4%, WHO 2010) in subjects with or without 
IDF&AHA/NHLBI-defined hypertension was 3.0 [1.0-7.0]  vs 6.0 [2.0-
10.0] (p<0.01). Since testis inhomogeneity was an important risk factor for 
abnormal morphology, even in an age- and TT-adjusted logistic model 
(HR=3.68 [1.99-6.82], p<0.0001), we tested the effect of introduction of 
testis inhomogeneity on the relationship between IDF&AHA/NHLBI-
defined hypertension and  abnormal morphology. In an age- and TT-
adjusted logistic model, both testis inhomogeneity and hypertension were 
found to be independent risk factors for poor sperm morphology (HR=3.44 
[1.82-6.53], p<0.0001 and HR=1.86 [1.02-3.39], p<0.05, respectively). No 
other associations between MetS and  semen parameters were observed 
(data not shown).  
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Sexual parameters 
When subjects with ED (IIEF-15-EFD score < 26) were divided 
according to the presence of MetS, those satisfying MetS criteria had a 
higher ED prevalence (46.2% vs. 16.7%, p=0.001). These results were 
confirmed after exclusion of subjects with diabetes mellitus (n=3) from the 
analysis (data not shown). The association was confirmed in a logistic 
model, after adjustment for age and TT (HR=2.86[1.18-7.31], p<0.05). At 
univariate analysis, the risk of ED increased as a function of MetS 
components (RR=1.56 [1.22-2.01]  p<0.0001 for each increment in the 
number of MetS components), and this association was confirmed after 
adjusting for the aforementioned confounders (HR=1.45[1.08-1.95], 
p<0.02,  for each increment in the number of MetS components, Figure 1 
D). In an age- and TT-adjusted logistic model, the MetS factors positively 
associated with ED were increased waist (HR=2.92 [1.28-6.63], p<0.02) 
and blood pressure (HR=2.33 [1.1-4.9], p<0.05, Figure 2D).  
When penile basal CDU was considered, arterial peak systolic 
velocity and acceleration were negatively related to MetS components, 
even after adjusting for age and TT (B=-0.748±0.314 , p<0.02 and B=-
0.201±0.092, respectively, both p < 0.05). These results were confirmed 
after exclusion of subjects with diabetes mellitus (n=3) from the analysis 
(data not shown). 
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No association between PEDT score and MetS was observed (not 
shown) and no difference in PE prevalence was found comparing subjects 
with or without MetS (22.2% vs 14.4%, p=0.283). 
 
Psychological parameters 
At univariate analysis, patients with MetS showed a significantly 
higher score in  MHQ-somatization (MHQ-S; 2.962±2.821 vs. 
1.857±2.266,  p=0.022) and depression scales (MHQ-D; 4.578±2.845 vs. 
3.004±2.516,  p=0.011). Scores for these two MHQ subscales were 
associated with numbers of MetS factors in both an unadjusted and in age- 
and TT- adjusted models (MHQ-S: unadjusted r = 0.126, adjusted  B=0.66 
± 0.03, for each increment in the number of MetS components, both 
p<0.05; MHQ-D unadjusted r = 0.197, p=0.001, adjusted B= 0.69 ± 0.03 
for each increment in the number of MetS components, p<0.02).   
 
Case-control analysis  
The correlations between MetS and seminal, ultrasound and sexual 
parameters resulting statistically significant were further assessed by 
comparing subjects with MetS with a 1:3 ratio matched controls (matched 
for age, body mass index, TT, smoking habit, alcohol consumption, past or 
present cryptorchidism, leukocytospermia, current positive urine and/or 
semen cultures; see Table 4). Even in the case-control analysis, subjects 
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with 3 or more MetS components showed a significantly increase in 
prevalence of abnormal  morphology and testis inhomogeneity (Table 4). In 
addition, subjects with ≥ 4 MetS factors had more often ED (Table 4).  
 
Effect of increasing number of MetS factors on reproductive health 
In order to assess if, in MetS subjects, having ≥ 4 components has a 
more negative impact on reproductive health than having only 3 
components, a comparison of the aforementioned parameters was 
performed between the two groups (Table 4). Subjects with ≥ 4 MetS 
factors were older, had a higher body mass index, were more often affected 
by ED and characterized by a lower TT levels compared to those with 3 
components only (Table 4). No significant difference in normal sperm 
morphology and prevalence of testis ultrasound homogeneity was observed 
between the two groups (Table 4).   
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Discussion 
This study demonstrates, for the first time, a component-dependent, 
stepwise association between the presence of MetS and abnormal semen 
parameters, along with several psychobiological factors which might 
further negatively impact male reproductive potential. In particular, we 
confirm, in subjects seeking medical care for male infertility, a clear-cut 
association between increasing numbers of MetS components and severity 
of male hypogonadism, previously reported in other patient populations 
(Muller et al., 2005; Corona et al., 2006, 2009a). Both total and calculated 
free T were reduced as a function of MetS factors. In particular, we found 
that having ≥  four MetS components exert a much more negative impact 
on TT levels than having only three. The finding that gonadotropins did not 
rise according to the androgen fall, indicates an hypogonadotropic nature of 
the hypogonadism, as previously described in studies performed on animal 
models of MetS (Filippi et al., 2009; Corona et al., 2011b) and in human 
cohorts (Corona et al., 2009b; Dandona et al., 2011). Accordingly, MetS 
triplicates the risk of having secondary hypogonadism, and secondary 
hypogonadism resulted the most common, infertility-associated, condition 
in subjects with MetS.  When the contribution of individual MetS 
components was investigated, we found that increased visceral adiposity 
(waist) and dyslipidemia (reduced HDL-cholesterol and elevated 
triglycerides) were the main determinants of testosterone decline. 
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Interestingly, increased waist was found as the main determinant for testis 
inhomogeneity, indicating a specific pathogenetic role for adiposity-related 
factors in testicular abnormalities. Testis inhomogeneity at ultrasonography 
is suggestive of atrophy and fibrosis (Cohn et al., 1996; Loberant et al., 
2010) and may reflect changes in the functional activity of the testis (Lenz 
et al., 1993; Behre et al., 1995). In fact, in the aging testis, atrophy of the 
tubular elements and proliferation of interstitial ones produce an 
exaggeration of the normally-unapparent septal and interstitial architecture, 
resulting in a striated appearance (Loberant et al., 2010). While a similar 
appearance is often observed in the elderly and considered normal, in 
young subjects it is recognized in a variety of pathological conditions, 
including hypogonadism (Cohn et al., 1996; Loberant et al., 2010; 
Migaleddu et al., 2012).  Present data suggest that a secondary 
hypogonadism is predominantly associated to MetS, and in particular to 
visceral adiposity. Visceral adiposity is also the main determinant of testis 
inhomogeneity. The latter can derive from a decreased testicular 
stimulation, because of a central defect, and/or from a direct effect of 
visceral adiposity on testis itself (mixed hypogonadism), as previously 
reported in other patient cohorts (Corona et al., 2008b, 2009b). Several 
molecules, such as insulin, estrogens, leptin, tumor necrosis factor α 
(TNFα) or other adipokines, mainly related  to increased adiposity, have 
been hypothesized to induce MetS-related hypogonadism, acting both at a 
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central or at a peripheral level (see for review Corona et al., 2011b).  In 
contrast to the positive association between hypogonadism and MetS, 
varicocele was less often found in subjects fulfilling MetS criteria, thus 
confirming the view that obesity is a protective factor against varicocele 
(Handel et al., 2006; Nielsen et al., 2006; Tsao et al., 2009). 
We here describe that there is a specific association between MetS and 
some sperm parameter abnormalities, including abnormal forward motility 
and morphology. These are two well recognized sperm parameters for 
successful fertilization both in vitro and in vivo (Chan et al., 1989;  Joshi et 
al., 1996; Donnelly et al., 1998). However, after adjusting for testosterone 
levels, only abnormal morphology retained a specific association with 
MetS, suggesting that hypogonadism, more than MetS itself, is responsible 
for the decreased progressive motility. We also reported that testis 
inhomogeneity was associated with abnormal morphology, as previously 
described (Lenz et al., 1993).  The MetS factor specifically associated with 
this abnormality was hypertension, and not visceral adiposity or other 
metabolic disturbances (hyperglycemia, dyslipidemia). Hypertension 
increased by a factor of two the risk of abnormal morphology, 
independently from other factors, such as testis inhomogeneity and 
testosterone levels. Mechanisms by which hypertension might affect sperm 
morphology are far from being understood  (Kasturi et al., 2008). Akagashi 
et al. (1997) found an extreme spermatogenic impairment in the form of 
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atrophic seminiferous tubules devoid of spermatids in stroke-prone 
spontaneously hypertensive rats. Very recently, a study of semen quality in 
hypertensive men demonstrated an association between hypertension with 
more fragmented/abnormal sperm DNA and with increased expression of 
clusterin, an apoptosis-associated protein, which identifies a subset of 
morphologically altered spermatozoa not necessarily dead  (Muciaccia et 
al., 2012). In that study (Muciaccia et al., 2012) the link between elevated 
blood pressure and abnormal morphology/DNA fragmentation was not 
clarified, but it was hypothesized that hypertension induces, within the 
testis, a generally altered vascular status characterized by  enhanced ROS 
generation  and limited antioxidant defense (Sharma et al., 1999; Brownlee, 
2005; Amaral et al., 2008). Another recently published report (Mbah et al., 
2012) indicates that treating normotensive, oligospermic  men with a low-
dose angiotensin converting enzyme (ACE) inhibitor (lisinopril, 2.5 
md/daily) ameliorates, in a rigorous placebo-controlled, crossover design,  
semen parameters, including sperm number, motility and morphology.  In a 
rabbit model of MetS, also characterized by hypertension,  we observed an 
increase in advanced glycation end products and their receptor (RAGE) in 
the seminiferous epithelium and in the cytoplasm of Sertoli cells, 
spermatocytes and spermatids, respectively (Mallidis et al., 2009). 
Accumulation of advanced glycation end products and their receptor 
RAGE are thought to be capable of generating, promoting and/or 
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amplifying oxidative stress and its detrimental consequences, including 
DNA damage (Sakkas and Alvarez, 2010). More studies are advisable to 
verify whether hypertension is associated with DNA fragmentation in 
subjects with MetS.  
ED (IIEF-15-EFD score < 26) was present in ~20% of the study 
cohort. This prevalence is essentially in agreement with previous reports in 
infertile men  (Jain et al., 2000; O'Brien et al., 2005; Shindel et al., 2008; 
Lotti et al., 2012), but is at least double that observed in the general Italian 
population, when subjects with a similar mean age are considered 
(Parazzini et al., 2000; Mirone et al., 2004). The prevalence of ED in our 
patient population was further increased by the MetS condition, with 
hypertension and visceral adiposity as the main determinants. In addition, 
we found that having ≥ four MetS components exerts the maximal negative 
impact on sexual function. Also PCDU-measured penile blood flow was 
decreased as a function of MetS severity. Similar results were reported in 
other studies (Corona et al., 2006; Demir et al., 2009; Tomada et al., 2011). 
Interestingly, in this study, the association between an increasing number 
of MetS components and both ED and reduced penile blood flow were 
independent from low testosterone. The lack of association between MetS 
and premature ejaculation (PE or PEDT score) was expected according to 
previous studies of our group (Corona et al., 2008c, 2011c, 2012), where 
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hypogonadism was more prevalent in delayed than in premature 
ejaculation.  
Not only ED, but also depressive symptoms and dysfunctional sexual 
relationship have been previously reported in subjects with couple 
infertility (Shindel et al., 2008; Smith et al., 2009; Lotti et al., 2012). It is 
well known that infertile men may develop feelings of inadequacy, anxiety, 
guilt and depression (Irvine & Cawood, 1996; Seidman & Roose, 2000). 
We now report that MetS severity further increases these negative 
emotions. In fact, both depressive symptoms and somatized anxiety were 
more prevalent in infertile men with MetS. MetS is highly prevalent among 
patients with a history of depression, especially those with current major 
depression (Heiskanen et al., 2006), perhaps because of increased body 
fatness or lifestyle alterations. However, previous prospective data 
indicated that depression, hostility and anger predict increased risk of MetS 
(Goldblacher & Matthews, 2007). Association between MetS and 
somatized anxiety was previously described by our group in subjects with 
sexual dysfunction (Corona et al., 2006). Somatization, which is the 
expression of physical symptoms in the absence of medically explained 
physical illness, might be viewed as a part of maladaptive thought or 
behaviour, or just as a dysfunctional response, to the infertility condition 
itself – an often unaccepted or unrecognised medical condition. We here 
report that having MetS increases somatization and depression scoring, 
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thus increasing the high attention devoted by these subjects to their body 
and possible bodily malfunctioning and therefore freezing several aspect of 
couple's sexual behaviour, including sexual desire and intercourse 
frequency (Corona et al., 2008d), further exacerbating the infertility 
condition.  A large body of evidence indicates that infertility evokes more 
general psychological distress in women than in men (Jordan & Revenson, 
1999). Accordingly, supportive psychosocial interventions  are thought to 
be more beneficial for the female than for the male partner of the infertile 
couple (Hammerli et al., 2009). It is possible that MetS-associated negative 
emotions and sexual dysfunctions reduce this gender-related gap in 
psychological distress. Further studies are advisable to clarify this point.   
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                Study 1 conclusions 
MetS is a set of metabolic risk factors originally proposed as a 
diagnostic tool because of its potential in identifying subjects at risk for 
diabetes and cardiovascular diseases, with the idea that its components 
could somehow have a synergistic effect on predicting unfavourable 
events. Later on, it became clear that other medical conditions are 
comorbid with MetS, including male hypogonadism and erectile 
dysfunction (Corona et al., 2009a, 2011a, 2011b). We now report that an 
increasing number of MetS factors are dose-dependently associated with 
relevant organic (poor sperm quality, hypogonadism, ED) and 
psychological (depression, somatization) features that might affect 
reproductive outcomes of men seeking medical care for couple infertility. 
This might tailor ad hoc therapeutic intervention. Behavioural interventions 
targeting lifestyle factors, such as dietary practice and physical activity, 
might ameliorate not only metabolic and psychological parameters but also 
male infertility, as has been demonstrated for female infertility. 
Recognizing the umbrella condition termed “metabolic syndrome” might 
therefore represent a unique occasion to improve not only reproductive 
health, but also psychological, sexual and overall health.  
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                STUDY 2 
 
METABOLIC SYNDROME AND PROSTATE 
ABNORMALITIES IN MALE SUBJECTS OF INFERTILE 
COUPLES 
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Materials and Methods 
We retrospectively evaluated a consecutive series of 187 male patients 
(age: 36.5±8.3 years) who attended our Outpatient Clinic initially between 
January 2010 and December 2011 seeking medical care for infertility. 
Based on guidelines of the World Health Organization, infertility was 
defined as the inability of a sexually active couple to achieve pregnancy 
despite unprotected intercourse over a period of greater than 12 months
 
(WHO, 2000). Subjects with karyotype abnormalities (n=3), chromosome 
Y micro-deletions (n=2) or an absence of at least one vas deferens and/or 
one seminal vesicle (n=11) were excluded from the analysis. Hence, a 
cohort of 171 selected patients was used for the analyses. The socio-
demographic and clinical phenotype of the sample population is 
summarised in Table 1. 
All patients were evaluated prior to any treatment. All enrolled 
patients underwent the typical diagnostic protocol used for infertility in 
newly referred subjects at the Andrology Outpatient Clinic. They 
underwent a complete andrological and physical examination and blood 
pressure (mean of three measurements taken 5 min apart in the sitting 
position using a standard sphygmomanometer), height, weight and waist 
circumference were measured. In addition, routine scrotal and transrectal 
ultrasounds were performed because our Regional Health Care System 
does not allow any genetic analysis on infertile patients unless a suspected 
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obstruction has been evaluated. All data were collected as part of the 
routine clinical procedure; therefore, based on Italian law, approval from 
the local Ethical Committee was not required. In addition, at the time of the 
initial visit, all patients provided written, informed consent to have their 
clinical records included in a dedicated database to be used, anonymously, 
for clinical research purposes. 
 
MetS assessment 
MetS was defined, based on the National Cholesterol Education 
Program Third Adult Treatment Panel
 
(NCEP-ATPIII, 2001) (see Appendix 
1), as the presence of three or more of the following five factors: central 
obesity (waist circumference >102 cm), elevated triglycerides (≥1.7 
mmol/L or treated for elevated triglycerides), elevated blood pressure 
(systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 
mmHg or treated for hypertension), elevated fasting glucose (≥6.1 mmol/L 
or treated for diabetes) and reduced high-density lipoprotein (HDL) 
cholesterol (<1.03 mmol/L or treated for dyslipidaemia). 
 
Biochemical parameters 
Blood samples were drawn in the morning after an overnight fast to 
determine blood glucose (using the glucose oxidase method; Aeroset 
Abbott, Rome, Italy), HDL cholesterol and triglycerides (using the 
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automated enzymatic colourimetric method; Aeroset Abbott, Rome, Italy), 
total testosterone (TT, using the electrochemiluminescent method; Modular 
Roche, Milan, Italy), insulin levels and sex hormone binding globulin 
(SHBG) using an electrochemiluminescence immunoassay (Roche 
Diagnostics, Mannheim, Germany). Free testosterone was calculated based 
on Vermeulen’s formula (available at http: //www.issam.ch/freetesto.htm) 
(Vermeulen et al., 1999). 
 
Semen analyses and determination of seminal plasma interleukin 8 
(sIL-8) levels  
On the same day as the ultrasound, all patients underwent semen 
analysis, which was performed based on World Health Organization criteria
 
(WHO, 2010). In addition, routine urine and seminal cultures were assessed 
in all men. Furthermore, sIL-8, a reliable surrogate marker of prostatitis
 
(Penna et al., 2007) was also quantified. Seminal plasma aliquots were 
frozen and stored for later quantification of sIL-8 levels using conventional 
two-site ELISA (human IL-8 ELISA set; BD Biosciences, San Diego, CA, 
USA) according to the manufacturer’s instructions (Penna et al., 2007). 
Each seminal plasma sample was diluted from 1:5 to 1:625. Assay 
sensitivity for sIL-8 was <1 pg/ml. 
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Screening of prostate-related symptoms and LUTS 
Patients were asked to complete the Italian translation of the National 
Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI)
 
(Litwin 
et al., 1999) (Appendix 5), which is a brief self-reported questionnaire for 
screening prostatitis symptoms and that scores for pain, voiding symptoms 
and quality of life (QoL). The NIH-CPSI total score was calculated as the 
sum of the scores of these domains. LUTS were evaluated using the Italian 
translation of the International Prostate Symptom Score (IPSS) (Appendix 
6), which is a brief self-administered questionnaire for screening symptoms 
related to BPH and that comprises seven questions on symptoms and one 
question on QoL
 
(Barry et al., 1992). 
 
Transrectal colour-Doppler ultrasonography (CDU) 
 We previously reported an association between MetS and scrotal 
parameters in a larger cohort of subjects who attended our unit for 
infertility (Lotti et al., 2013a). The characteristics of that cohort were not 
different from the cohort in this study; thus, in this study, we focused on the 
possible associations between MetS and transrectal ultrasound features.  
 All patients underwent scrotal and transrectal CDU; the latter before 
and after ejaculation. To prevent bias on the part of the examiner, scrotal 
and transrectal CDU was performed intermittently by two experienced 
physicians who were unaware of the clinical data and who used the same 
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ultrasonographic console (Hitachi H21, Hitachi Medical System, Tokyo, 
Japan). Prostate and seminal vesicle CDU features were studied by 
scanning the organs at 5 mm intervals at various longitudinal, transverse 
and oblique scans based on previous studies
 
(Behre et al., 1995; Vicari, 
1999; Lotti et al., 2011a,b, 2012) using a transrectal biplanar probe (linear 
transducer U533L 7.5 MHz; convex transducer U533C 6.5 MHz) and an 
“end fire” probe (V53W 6.5 MHz, field of view 50°–200°). Based on: 1) 
antero-posterior (APD) and 2) transverse (TD) diameters at the maximal 
dimensions and 3) the superior-inferior or longitudinal diameter (LD) at the 
maximal length from the base to the apex of the midline sagittal plane, 
prostate volume was calculated using the formula of the ellipsoid (APD x 
TD x LD x π/6) based on previous publications (Lotti et al., 2011b; Collins 
et al., 1995; St Sauver et al., 2006). During this exam, similar methods 
were also used to determine the transitional zone volume (TZV) based on a 
previous publication
 
(St Sauver et al., 2006). Prostate echogenicity was 
defined based on previous studies (Behre et al., 1995; Vicari, 1999; Lotti et 
al., 2011a,b). The severity of prostate texture non-homogeneity was 
classified using an arbitrary Likert scale and scores of 0–3 
(0=homogeneous texture, 1=mild, 2=moderate and 3=severe texture non-
homogeneity). Prostate vascularisation, prostate hyperaemia and arterial 
prostatic peak systolic velocity (APPSV) were defined based on previous 
studies (Lotti et al., 2011a,b; Cho et al., 2000; Lotti et al., 2012b)
  
and 
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evaluated prior to ejaculation to avoid post-ejaculatory changes in vascular 
flow pattern as has been previously reported (Keener et al., 2000). Seminal 
vesicle ultrasound features and abnormalities were defined based on 
previous studies (Colpi et al., 19997; Vicari, 1999; Lotti et al., 2011a, 
2012a; 2013b). Ejaculatory duct CDU characteristics were evaluated after 
ejaculation to better emphasise indirect CDU signs of subobstruction (Colpi 
et al., 1997; Lotti et al, 2011a, 2012a). 
Scrotal CDU was performed systematically using a 7.5 MHz high-
frequency linear probe (L54M 6-13 MHz) at various longitudinal, 
transverse and oblique scans with patients lying in a supine position (Behre 
et al., 1995; Vicari, 1999; Lotti et al., 2011a). Testicular and epididymal 
CDU features were examined based on previous studies (Behre et al., 1995; 
Vicari, 1999; Lotti et al., 2011a). 
 
Identification of case patients and controls 
MetS was defined as described above. Subjects with ≥3 MetS 
components (n=22) were compared with controls selected from the same 
cohort at a 1:2 ratio (n=44). For each case, the first two patients following 
those with MetS within the same series who were the same age (±4 years 
old) and who showed a similar TT level (±4 nmol/L), smoking habit 
(current/non-smoker) and moderate-severe alcohol consumption 
(current/no consumption of ≥4 drinks per day based on a previous 
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publication; Boddi et al., 2010).
 
For statistical analyses that compared cases 
with age-, TT-, smoking habit-, moderate-severe alcohol consumption-
matched controls, associations with P<0.05 were considered significant. 
 
Data analyses 
Data were expressed as the mean±s.d. when normally distributed, the 
median (quartiles) for parameters with non-normal distributions, and as 
percentages when categorical. Correlations were assessed using 
Spearman’s or Pearson’s methods as appropriate. Differences between 
more than two groups were assessed using one-way ANOVAs. Unpaired 
two-sided Student’s t test was used to compare means of normally 
distributed parameters. Relative risks and 95% confidence intervals were 
calculated for correlations of categorical parameters, and chi-squared tests 
were used for comparisons. Stepwise multiple linear, logistic binary or 
ordinal regressions were applied for multivariate analyses as appropriate. 
All statistical analyses were performed in SPSS (Statistical Package for the 
Social Sciences, Chicago, USA) for Windows 20.0. 
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                Results  
Among the 171 patients studied (age: 36.6±8.4), 44.4% (n=76) 
showed no components of MetS whereas one, two, three, four and five 
MetS factors were present in 47 (27.5%), 26 (15.2%), 16 (9.4%), 3 (1.75%) 
and 3 (1.75%) subjects, respectively. Twenty-two subjects (12.9%) fulfilled 
the criteria of NCEP-ATPIII MetS. Subjects with MetS were older 
(43.8±10.6 vs. 35.5±7.5 years for MetS and no-MetS subjects, respectively; 
P<0.0001). No difference in the percentage of subjects who smoked 
currently or consumed moderate-severe amounts of alcohol was found 
when MetS and no-MetS subjects were compared (21.1% vs. 28.6%, 
P=0.496; 16.7% vs. 24.8%, P = 0.233; MetS vs. no-MetS subjects, 
respectively). In addition, no difference in the prevalence of 
leukocytospermia or current positive urine and/or seminal cultures was 
observed when men with and without MetS were compared (5.3 vs. 8.8%, 
P 0.508; 5.6 vs. 8.1%, P=0.575; MetS vs. no-MetS subjects, respectively).  
 
Correlations of MetS with hormonal, clinical and semen parameters  
 Age-adjusted logistic ordinal models showed that insulin levels 
increased as a function of MetS components (Wald=29.5 [0.09–0.18], 
P<0.0001; Figure 1A). Figure 1B–1D also showed the age-adjusted 
relationships between insulin and TT, SHBG and calculated free 
testosterone: all of these parameters decreased as a function of increasing 
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insulin levels (adjusted r=-0.359, P<0.0001; adjusted r=-0.200, P<0.001; 
adjusted r=-0.320, P<0.0001, respectively). In view of these associations, 
all the following analyses were adjusted for age, insulin and TT levels.  
Digito-rectal examinations revealed that an enlarged prostate was 
positively associated with the number of MetS components (HR=1.47 
[1.03–2.14] for each increment in the number of MetS components, 
P<0.05). Of the semen parameters, only normal semen morphology was 
negatively associated with an increasing number of MetS components 
(Wald=5.59 [-0.15–-0.01], P<0.02).  
No association between MetS components and other physical or 
seminal parameters including leukocytospermia was observed (not shown). 
Finally, no association between MetS components and current positive 
urine and/or seminal cultures was detected (not shown). 
 
Correlations of MetS with prostate-related symptoms and signs (sIL-8) 
No association was found between MetS and prostate-related 
symptoms as captured by both NIH-CPSI and IPSS (not shown). A 
stepwise, positive correlation between the number of MetS components and 
sIL-8 levels was observed (Wald=4.32 [0.04–1.48], P<0.05; Figure 2A). In 
particular, among the MetS components, only waist circumference was 
positively associated with sIL-8 (Figure 2B). 
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Correlations of MetS with transrectal ultrasound parameters 
 A progressively higher prostate volume was detected by ultrasound as 
a function of an increasing number of MetS components (Wald=17.6 [0.05–
0.13], P<0.0001; Figure 2C). In a logistic iterative analysis, of the MetS 
factors, waist size and reduced HDL cholesterol were significantly 
associated with prostate volume (Figure 2D). Interestingly, TZV was 
positively correlated with total prostate volume even after adjusting for the 
aforementioned confounders (adjusted r=0.757, P<0.0001). Thus, TZV also 
increased as a function of an increasing number of MetS components 
(Wald=12.5 [0.07–0.24], P<0.0001). In addition, TZV of MetS subjects 
was significantly higher than other subjects (10.7±10.8 vs. 3.9±2.6 ml; 
P<0.0001; subjects with MetS vs. those without MetS, respectively). 
Finally, similarly to total prostate volume results, TZV was significantly 
associated with reduced HDL cholesterol levels (HR=1.15[1.01-1.31], 
P<0.05). Conversely, only a trend towards statistical significance was 
observed for increased waist (HR=1.11 [0.99–1.24], P=0.08). 
A positive association between an increasing number of MetS 
components was also observed for some ultrasonographic prostate features, 
such as arterial peak systolic velocity (APPSV, Wald=9.57 [0.05-0.24], 
P=0.002; Figure 3A) and diameter of the major calcification (Wald=3.11 
[0.01–0.13], P<0.05; Figure 3C). Using a binary logistic model, moderate-
severe prostate texture non-homogeneity was also associated with an 
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increase in the number of MetS components (HR=1.87 [1.05–3.33] for each 
increment in the number of MetS components, P<0.05; Figure 3C). Of the 
MetS components, only increased waist circumference was significantly 
associated with APPSV (Figure 3B) and with moderate-severe texture non-
homogeneity (Figure 3D). After adjusting for confounders, no associations 
between MetS related-prostate CDU abnormalities and standard semen 
parameters were observed (Table 2). Finally, no associations between the 
number of MetS components and seminal vesicle features or the mean 
diameter of the deferential ampulla were observed (data not shown). 
 
Case-control analyses  
Correlations between MetS and seminal or ultrasound parameters 
showing statistical significance were further assessed by comparing 
subjects with MetS with matched controls (matched for age, TT, smoking 
habit and moderate-severe alcohol consumption; Table 3) at a 1:2 ratio. 
Even in the case-controlled analyses, subjects with three or more MetS 
components showed a lower percentage of normal sperm morphology, 
higher sIL8 levels and more frequent prostate abnormalities, such as greater 
volume, higher arterial peak systolic velocity, greater calcification size and 
prevalence of moderate-severe non-homogeneity (Table 3). No difference 
in the prevalence of leukocytospermia or current positive urine and/or 
seminal cultures was observed when MetS subjects were compared with 
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controls (Table 3). 
 
Correlations of insulin levels with clinical, seminal and transrectal 
ultrasound parameters 
Univariate analyses revealed positive associations between insulin 
levels and increased prostate volume detected by either digito-rectal 
examination (RR=1.08 [1.03–1.14], P=0.002 for each insulin mU/L 
increment) or ultrasound (r= 0.294, P<0.0001), moderate-severe texture 
non-homogeneity (RR=1.08 [1.00–1.17], P=0.05 for each insulin mU/L 
increment), hyperaemia (RR=1.05 [1.00–1.11], P<0.05 for each insulin 
mU/L increment) and arterial peak systolic velocity (r=0.286, P<0.0001) 
and a negative correlation with the prostatic venous plexus diameter (r=-
0.180, P<0.02). When a multivariate regression model was applied that 
included age and TT, the significant associations between insulin levels and 
prostate volume detected both by digito-rectal examination (HR=1.07 
[1.01–1.13], P<0.05 for each insulin mU/L increment) and ultrasound 
(adjusted r=0.327, P<0.0001; Figure 4A) and arterial peak systolic velocity 
(adjusted r=0.229, P=0.002; Figure 4B) were confirmed. However, when 
the number of MetS components was introduced into the same model, only 
prostate volume detected by ultrasound was significantly associated with 
insulin levels (adjusted r=0.171, P<0.05). 
Even after adjusting for the aforementioned confounders, no 
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associations between insulin levels and semen parameters, sIL-8 levels, 
seminal vesicle features or diameters of the deferential ampulla were 
observed (data not shown). 
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                      Discussion 
This study demonstrates that in a cohort of relatively young male 
subjects examined for infertility, a stepwise, component-dependent 
association was observed between an increase in MetS severity and 
prostate enlargement and/or inflammatory signs (including sIL-8 levels and 
CDU abnormalities) but not with current infection of the male genital tract. 
No association between MetS-related prostate CDU abnormalities and 
semen parameters was detected. However, in this cohort, MetS was 
associated with poor sperm morphology. Reduced HDL levels and 
increased abdominal adiposity were the main correlates of prostate 
enlargement in this young, asymptomatic cohort.  
The association between MetS and prostate enlargement is consistent 
with several previous reports
 
(Gacci et al., 2013; Hammarsten et al., 1998; 
Hammarsten and Högstedt 1999, 2001; Ozden at al., 2007; Sohn et al., 
2007; Park and Park 2007; Koo et al., 2008; Byun et al., 2012). Thus far, 
only a few studies have examined relatively young adults, and they offer 
conflicting results
 
(Jeong et al., 2011; Yim et al., 2011). Here, we report a 
novel association in a relatively young population (mean age 36.6±8.4 
years) of males of infertile couples. Increased central obesity and reduced 
HDL cholesterol were the parameters that most closely correlated with 
prostate enlargement. A potential relationship between BPH/prostate 
enlargement and obesity or increased waist circumference has been widely 
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reported in several (Mongiu and McVary, 2009; Parsons, 2013), but not all 
previous studies (Gacci et al., 2013). Moreover, low HDL cholesterol has 
been previously reported as a risk factor for the development of BPH 
(Gacci et al., 2013; Hammarsten et al., 1998; Hammarsten and Högstedt 
1999, 2001; Ozden at al., 2007). Our data suggest that MetS, and 
particularly high waist circumference and reduced HDL cholesterol, may 
play an important role in prostate growth onset at a young age. 
We also noted a significant, stepwise correlation between the number 
of MetS components and seminal IL-8 (sIL-8), which has been proposed as 
a surrogate marker of prostate inflammation
 
(Penna et al., 2007; 2009; 
Fibbi et al., 2009; Lotti and Maggi, 2013). IL-8 is a proinflammatory 
chemokine that is secreted by several cell types and that contributes to 
inflammation by acting in concert with IL-1β and IL-6 (Steiner et al., 2002; 
Baggiolini et al., 1995; Feldmann et al., 2001). Higher IL-8 levels have 
been reported in the expressed prostatic secretions of subjects with BPH, 
bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome 
(CP/CPPS)
 
(Hochreiter et al., 2000; Orhan et al., 2001; Liu et al., 2009). 
Because IL-8 in seminal plasma is considerably higher when compared 
with serum levels (Shimoya et al., 1993; Koumantakis et al., 1998), local 
(within the male genital tract) production has been suggested (Koumantakis 
et al., 1998; Hochreiter et al., 2000; Lotti and Maggi, 2013). Of different 
cytokines and chemokines, sIL-8 appears to be the most reliable and 
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predictive surrogate marker of prostatitis (Penna et al., 2007; Fibbi et al., 
2009),
 
and it is associated with CDU features suggestive of prostate 
inflammation in patients with male accessory gland infection (MAGI) 
(Lotti et al., 2011a). IL-8 is actively involved in BPH-associated chronic 
inflammation and mediates epithelial and stromal cell proliferation (Fibbi 
et al., 2009). In BPH tissues, epithelial and stromal cells secrete IL- 8 
actively (Fibbi et al., Konig et al., 2004) in response to varying stimuli 
including the proinflammatory cytokines IFNγ and IL-17 that are produced 
by prostate-infiltrating Th1 and Th17 cells, respectively
 
(Penna et al., 2007; 
Steiner et al., 2003; Kramer et al., 2007; Adorini et al., 2010). In particular, 
human stromal prostatic cells actively contribute to the organ-specific 
inflammatory process by acting as targets of bacterial or viral toll-like 
receptors agonists and as antigen-presenting cells capable of activating 
antigen-specific CD4+ T cells
 
(Penna et al., 2009b). In BPH cells, toll-like 
receptor activation leads to the production of proinflammatory cytokines 
(IL-6) and chemokines (IL-8 and CXCL10) capable of recruiting CXCR1 
and CXCR2-positive leukocytes and CD15+ neutrophils (Penna et al., 
2007). Finally, IL-8 stimulates overgrowth of prostate stromal and 
epithelial cells by directly promoting the proliferation of senescent 
epithelial cells (Castro et al., 2004), stromal trans-differentiation of 
myofibroblasts (Schauer et al., 2008) and by increasing secretion of 
fibroblast growth factor 2 (Giri et al., 2001). Hence, IL-8 appears to be the 
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link between T-cell-mediated inflammatory responses and cell proliferation 
in the pathogenesis of BPH (Fibbi et al., 2009; Adorini et al., 2010). 
 
A higher prevalence of MetS components was also associated with 
other CDU features of prostate inflammation including texture non-
homogeneity, major calcification size and elevated APPSV. Increased waist 
size is the common determinant of all of these CDU abnormalities. Prostate 
non-homogeneity is typically considered a CDU abnormality related to 
inflammation (Behre et al., 1995) and has been previously associated with 
elevated sIL-8 levels in infertile subjects with MAGI (Lotti et al., 2011a). 
Moreover, prostatic hyperechogenicity, which is associated with areas of 
calcification, has been previously proposed to be a CDU feature suggestive 
of MAGI (Vicari, 1999). In particular, prostatic high-density echoes are 
considered the sonographic correlates of prostatic calculi and corpora 
amylacea, which as confirmed by histology performed on ultrasound-
guided biopsies of the prostate (Doble and Carter, 1989). A recent report 
indicated that prostatic calculi and corpora amylacea comprised acute 
inflammatory proteins including lactoferrin, calprotectin, mieloperoxidase 
and α-defensins, all of which are in neutrophil granules (Sfanos et al., 
2009). Prostatic calcifications are common in patients with CP and have 
been associated with the maintenance or enhancement of prostate 
inflammation, bacterial colonisation and duration of symptoms
 
(Meares, 
1974; Shoskes et al., 2007). A positive correlation between sIL-8 levels and 
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calcification size has also been previously reported by our group (Lotti et 
al., 2011a). Finally, we noted that APPSV correlated with MetS severity. 
Arterial PSV reflects tissue inflammation at various sites including the 
thyroid (Lagalla et al., 1998; Corona et al., 2008e), exocrine glands 
(Giovagnorio et al., 2000; Carotti et al., 2001) and synovial 
membrane/joints (Versamidis et al., 2005; Carotti et al., 2012). Thus far, 
APPSV has been studied for varying purposes including evaluation of BPH 
(Berger et al., 2006), prostate cancer (Turgut et al., 2007), varicocele-
related prostate CDU changes (Lotti et al., 2009) and premature ejaculation 
(Lotti et al., 2012b). More recently, elevated APPSV has been proposed as 
a CDU parameter that correlates with prostate inflammation (Lotti et al., 
2011a,b; 2012b), and in the prostate, APPSV is closely related to sIL-8 
(Lotti et al., 2011a).  
No correlation was found between the number of MetS components 
and current positive urine and/or seminal cultures suggesting that MetS is 
not associated with current infection of the male genital tract but is rather 
associated with chronic inflammation.  
The relationship between central obesity and dyslipidaemia with 
prostate overgrowth and inflammation, even in young subjects, is the main 
finding of this study. We previously reported a clear-cut association 
between MetS severity and prostate size (Gacci et al., 2013) and 
inflammation19,85 in cohorts of aged subjects. In the study of Gacci et 
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al.(2013), reduced HDL cholesterol and increased triglyceride levels were 
also noted to be the main determinants of MetS-related prostate alterations. 
However, previous studies were performed in old individuals undergoing 
surgery for BPH (Vignozzi et al., 2012a, 2013). By culturing BPH stromal 
cells obtained from those patients, we demonstrated that in addition to 
TNF-α and LPS, oxidised LDL (oxLDL) was capable of increasing IL-8, 
IL-6 and bFGF secretion (Vignozzi et al., 2013). In addition, TNF-α 
sensitised BPH cells to oxLDL by inducing its receptor (LOX-1) (Vignozzi 
et al., 2013). In a rabbit model of MetS we recently demonstrated that a 3-
month high-cholesterol diet (HFD) induced severe prostatic inflammation 
characterised by increased corpora amylacea, fibrosis and hypoxia 
(Vignozzi et al., 2012b). In addition, the mRNA expression of several 
proinflammatory cytokines including IL-8 and T lymphocyte, macrophage, 
neutrophil and fibrosis/myofibroblast activation markers were significantly 
increased in the prostate of HFD animals (Vignozzi et al., 2012b). Together, 
all of these data suggest that BPH may be viewed as a complex disorder 
that also involves a metabolic component that may begin early in the life of 
the male, and although asymptomatic, it is likely detectable even in the 
early stages of the disease as suggested by this study. The mechanisms 
underpinning the relationship between MetS and prostate inflammation are 
likely to be similar in young and old men but chronic exposure to elevated 
inflammation may contribute to BPH in the long term.  
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Because hyperinsulinaemia and insulin resistance represent the 
cornerstone of all definitions of MetS (Reaven, 2004; Eckel et al., 2010), 
all of the data reported here were adjusted for insulin levels. When the 
specific contribution of hyperinsulinaemia was considered, after adjusting 
for MetS components and total testosterone levels and age, we observed a 
specific effect of increased insulin levels only on prostate volume and not 
on prostate inflammation. This finding is in apparent contrast with results 
published recently by our group that showed that insulin increased IL-8 
release from myofibroblastic hBPH cells (Vignozzi et al., 2013). However, 
in that study, the effect of insulin was negligible when compared with 
oxLDL (six-fold lower) (Vignozzi et al., 2013). The growth-promoting 
activity of insulin on the prostate gland is well-documented in several 
experimental and epidemiological studies (Vikram et al., 2010). 
In this study, no association between an increase in the number of 
MetS components and prostate-related symptoms was observed, using 
either NIH-CPSI or IPSS scores. The lack of correlation between MetS and 
LUTS is consistent with some studies but contrasts with most previous 
studies (Moul and McVary, 2010; Gorbachinsky et al., 2010; De Nunzio et 
al., 2012)
 
. However, all previous studies were performed in aged cohorts 
whereas our data were obtained from young subjects with relatively small 
prostates as assessed by ultrasound. 
Finally, even after adjusting for confounders including the 
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hypogonadal status, we observed an association between the number of 
MetS components and poor sperm morphology. These results confirmed 
previous findings obtained using a larger cohort of males of infertile 
couples where we assessed the possible correlations of MetS with scrotal 
parameters (Lotti et al., 2013). The possible impact of MetS on sperm 
morphology was discussed in detail in that study. Here, we extend our 
investigation to possible associations between MetS-related prostate CDU 
features and semen parameters and note no correlation. This finding 
suggests that the effect of MetS on sperm quality is independent of MetS-
related prostate abnormalities. Although a possible association between CP 
or MAGI and sperm quality has been proposed and some prostate CDU 
features have been proposed as suggestive of MAGI (Vicari, 1999; Weidner 
et al., 1999; Krause, 2008; Rusz et al., 2012) a specific association between 
prostate CDU features and sperm parameters alterations has not been 
demonstrated. Here, we here report that the number of MetS components, 
but not related prostate CDU abnormalities, are associated with poor sperm 
morphology. 
This study has several limitations. First, the results were derived from 
patients consulting an Italian Andrology Clinic for infertility, and our 
population could have different characteristics from the general male 
population or those males consulting general practitioners for reasons other 
than infertility. Second, a true control group comprising age-matched, 
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apparently healthy, fertile men is lacking and therefore true normative data 
on sonographic parameters cannot be inferred. Third, the data cannot 
distinguish between men who are clinically infertile and those who are not, 
and whether this feature confounds the results is unknown. Fourth, this 
study relies on a relatively small and young sample. Fifth, markers of 
prostate inflammation other than sIL-8 are lacking. Furthermore, parallel 
mechanistic studies to determine the consequences of IL-8 secretion on 
prostate growth and differentiation are warranted. Finally, the link between 
MetS or insulin levels and prostate enlargement in this study are correlative 
only. Statistically significant associations in a cross-sectional study do not 
infer causality. 
However, this study also has several strengths. First, this study 
systematically evaluates several hormonal, seminal, laboratory and 
ultrasound parameters in a consecutive series of males of infertile couples. 
Second, during the same sonographic session, this study examined both 
scrotal and transrectal ultrasound features before and after ejaculation. 
Third, this study was performed on a sample of relatively young, infertile 
men and investigated a population that is poorly studied in the scientific 
literature. Fourth, this study considers several possible confounders, such 
as age, testosterone and insulin levels, smoking habits, alcohol 
consumption, leukocytospermia and positive semen and urine cultures of 
the patients. Fifth, a statistical analysis comparing patients with MetS with 
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age-, total testosterone-, smoking habits-, alcohol consumption-matched 
controls was performed. Finally, the study examined several end points 
simultaneously within the same population, which enabled a valid 
comparison of the co-prevalence of the examined parameters and supported 
their possible association with the number of MetS components.  
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Study 2 conclusions 
This study demonstrates that in a cohort of men with infertility, a 
component-dependent, stepwise association was observed between an 
increase in the number of MetS components and the total and transitional 
zone prostate enlargement and prostate related-inflammatory signs but not 
symptoms or current infection of the male genital tract, which suggests a 
sub-clinical inflammation of the prostate. Relative prostate overgrowth may 
also correlate with MetS-related hyperinsulinaemic state. In addition, MetS 
but not MetS’s related prostate CDU abnormalities was associated with 
poor sperm morphology. 
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                FINAL CONCLUSIONS 
 
In men with couple infertility, MetS is associated with hypogonadism, 
poor sperm morphology, testis ultrasound inhomogeneity, erectile 
dysfunction, somatization and depression.  
In addition, MetS is positively associated with prostate enlargement, 
biochemical (seminal interleukin 8) and ultrasound-derived signs of 
prostate inflammation but not with prostate-related symptoms, which 
suggests that MetS is a trigger for a subclinical, early-onset form of benign 
prostatic hyperplasia. 
Recognizing MetS could help patients to improve not only fertility but 
also sexual and overall health. 
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                 STUDY 1 FIGURES AND TABLES 
 
 
 
Figure 1. Association between the prevalence of testis ultrasound (US) 
inhomogeneity (panel A), total testosterone levels (panel B), normal 
sperm morphology (panel C) and prevalence of erectile dysfunction 
(panel D) with the number of metabolic syndrome (MetS) components 
(IDF&AHA/NHLBI classification). Panel A, inset: ultrasonographic 
images of homogeneous (upper picture) and inhomogeneous (lower 
picture) testis. In every panel, the number of subjects with no, one or more 
MetS components is indicated. 
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Figure 2. Hazard ratio (95% confidence interval) for testis ultrasound 
(US) inhomogeneity (panel A), hypogonadism (total testosterone <12 
nmol/L) (panel B), abnormal sperm morphology (< 4%, WHO 2010) 
(panel C) and erectile dysfunction (ED; IIEF-15-EFD < 26) as detected 
by logistic regression analysis considering metabolic syndrome (MetS) 
components (IDF&AHA/NHLBI classification) as putative predictors. 
Panels A, C and D: data have been adjusted for age and total testosterone 
levels. Panel B: data have been adjusted for age. MetS components are 
defined by abnormal parameters or by specific therapy (t), according to 
IDF&AHA/NHLBI classification. 
 
 61 
 
Table 1. Clinical and scrotal colour-Doppler ultrasound characteristics 
of the whole sample and of subjects with or without (w/o) metabolic 
syndrome (MetS) (see below, page 62).  
Data are expressed as mean ± standard deviation or as median (quartiles), 
when appropriate, and as percentage, when categorical. HDL, high density 
lipoprotein; BP, blood pressure; FSH, follicle stimulating hormone; LH, 
luteinizing hormone; PRL, prolactin; TSH, thyroid stimulating hormone. 
Tp, therapy § echographic defined severe varicocele = basal venous reflux 
increasing after Valsalva’s manoeuvre at sonography (according to Isidori 
& Lenzi, 2008; Lotti et al., 2009).  
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Table 2: Etiological factors involved in male infertility in the whole 
sample and in subjects with or without (w/o) metabolic syndrome 
(MetS). % of subjects with MetS for each infertility factor. Data are 
expressed as percentage. CDU, colour-Doppler ultrasound. § Biochemical 
hypogonadism has been defined for total testosterone levels < 12 nmol/L, 
according to Wang et al. (2009). Secondary or primary hypogonadism has 
been defined for  LH ≤ 9.4 or > 9.4 U/L, respectively, according to Tajar et 
al. (2010). ^ clinical varicocele: any degree of varicocele (grade 1-3) 
according to Dubin & Amelar classification (Dubin & Amelar, 1970). ^^ 
CDU defined severe varicocele = basal venous reflux increasing after 
Valsalva’s manoeuvre at CDU (according to Isidori & Lenzi, 2008; Lotti et 
al., 2009). A statistical analysis comparing patients with and without MetS 
has been performed. * p <0.05; ** p < 0.0001 
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Table 3: Univariate and multivariate (age-adjusted) associations 
between metabolic syndrome components and hormonal parameters. 
cFT, calculated free testosterone; SHBG, Sex Hormone Binding Globulin; 
LH, luteinizing hormone; FSH, follicle stimulating hormone; PRL, 
prolactin; TSH, thyroid stimulating hormone. 
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Table 4. Comparisons between subjects with metabolic syndrome 
(MetS) and 1:3 ratio matched controls (matched for age, body mass 
index, total testosterone, smoking habit, alcohol consumption, past or 
present cryptorchidism, leukocytospermia, current positive urine 
and/or semen cultures). Comparison between subjects with ≥ 4 MetS 
components and 3 MetS components. Data were expressed as mean ± 
standard deviation when normally distributed, median (quartiles) when not 
normally distributed, and as percentages when categorical. BMI, body mass 
index. ED, erectile dysfunction. IIEF-15-EFD, International Index of 
Sexual Function-15 erectile function domain. 
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STUDY 2 FIGURES AND TABLES 
 
 
Figure 1. Association between insulin levels and the number of metabolic 
syndrome (MetS) components (NCEP-ATPIII classification) (A), total 
testosterone (B), sex hormone binding globulin (SHBG) (C) and calculated 
free testosterone levels (D). In (A), subjects with no, one or more MetS 
components are indicated. In (B–D), subjects with or without MetS are 
shown as filled or empty dots, respectively. 
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Figure 2. Association between metabolic syndrome (MetS) and seminal 
interleukin 8 (sIL-8) levels or prostate volume at ultrasound. Association 
between the number of MetS components (NCEP-ATPIII classification) 
and seminal interleukin 8 (sIL-8) levels (A) or prostate volume at 
ultrasound (C). The number of subjects with no, one or more MetS 
components is indicated. Hazard ratio (95% confidence interval) for sIL-8 
levels (B) and prostate volume at ultrasound (D) as detected by iterative 
logistic regression analyses considering MetS components as putative 
predictors. MetS components are defined by abnormal parameters or by 
specific therapy (t) based on NCEP-ATPIII groupings. 
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Figure 3. Association between metabolic syndrome (MetS) and arterial 
prostatic peak systolic velocity (APPSV), texture non-homogeneity and 
major calcification size of the prostate as evaluated using colour-Doppler 
ultrasound (CDU). Association between the number of metabolic syndrome 
(MetS) components (NCEP-ATPIII classification) and APPSV (A), 
moderate-severe non-homogeneity prevalence (C) or major calcification 
size (c, inset) of the prostate as evaluated using CDU. The number of 
subjects with no, one or more MetS components is indicated. Hazard ratio 
(95% confidence interval) for APPSV (B) and prostate moderate-severe 
non-homogeneity (D) as detected by iterative logistic regression analysis 
considering MetS components as putative predictors. MetS components are 
defined by abnormal parameters or by specific therapy (t) based on NCEP-
ATPIII groupings. m-s, moderate-severe. 
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Figure 4. Associations between insulin levels and prostate volume (A) or 
arterial prostatic peak systolic velocity (B) evaluated using colour-Doppler 
ultrasound (CDU). Subjects with or without metabolic syndrome are shown 
as filled or empty dots, respectively. 
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Table 1. Clinical and transrectal colour-Doppler ultrasound 
characteristics of the sample (see below, page 71). 
Data are expressed as the mean±s.d. or as the median (quartiles) where 
appropriate and as percentages when categorical. NIH-CPSI, National 
Institutes of Health Chronic Prostatitis Symptom Index; sIL-8, seminal 
interleukin 8; HDL, high-density lipoprotein; BP, blood pressure; tp, 
therapy. 
§
 Calcifications with size > 3 mm (Lotti et al., 2011a,b).  
° Calculated using the “ellipsoid/prolate (d1 > d2 = d3) spheroid” formula 
(d1*d2*d3*4/3*π, where d1 = ½ maximum longitudinal diameter of the SV 
and both d2 and d3 = ½ anterior-posterior maximum diameter; based on 
Lotti et al., 2013a). ^ Calculated as [(pre-ejaculatory total volume – post-
ejaculatory total volume)/pre-ejaculatory volume)] * 100 (based on Lotti et 
al., 2012a).  
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Table 2: Univariate associations between metabolic syndrome (MetS)-
related prostate colour-Doppler ultrasound (CDU) characteristics and 
semen parameters  
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Table 3. Comparisons between subjects with metabolic syndrome 
(MetS) and 1:2 ratio-matched controls (matched for age, total 
testosterone, smoking habits and moderate-severe alcohol 
consumption). The data are expressed as the mean ± standard deviation 
and as percentages when categorical. sIL8, seminal interleukin 8; CDU, 
colour-Doppler ultrasound. 
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Appendices 
 
              Appendix 1. Comparisons of definitions of metabolic 
syndrome: National Cholesterol Education Program-Third Adult 
Treatment Panel (NCEP-ATPIII), International Diabetes Federation (IDF), 
American Heart Association/National Heart, Lung and Blood Institute 
(AHA/NHLBI) and common definition by IDF and AHA/NHLBI. In blue 
are shared factors among different definitions (see Corona et al., 2011a) . 
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Appendix 2. International Index of Sexual Function-15  
(IIEF-15) (Rosen et al., 1997) 
 
“IIEF-15-erectile function domain”: questions #1-2-3-4-5-15  
(Cappelleri et al., 1997) 
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Appendix 3. Premature Ejaculation Diagnostic Tool (PEDT) 
(Symonds et al., 2007)  
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               Appendix 4. Middlesex Hospital Questionnaire (MHQ) 
               (Crown & Crisp, 1966) 
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                    Appendix 5. National Institutes of Health Chronic Prostatitis 
Symptom Index (NIH-CPSI) (Litwin et al., 1999) 
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                         Appendix 6. (Barry et al., 1992) 
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